What question did this study set out to answer?

To evaluate whether adding rosuvastatin to standard heart failure therapy provides incremental improvements in cardiac structure and function in a rat model of hypertensive heart failure with preserved ejection fraction.

July 2, 2010European Journal of Heart FailureOpen Access

Rosuvastatin Added to Standard Heart Failure Therapy Improves Cardiac Remodelling in Heart Failure Rats with Preserved Ejection Fraction

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Heart failure with preserved ejection fraction (HFpEF). Intervention: Rosuvastatin plus standard HF therapy (quinapril, torasemide, carvedilol) vs. Non-treated, rosuvastatin alone, or standard HF therapy alone. Primary outcome: Cardiac structure and function (LV chamber dilatation, cardiac hypertrophy, fibrosis, and inflammation).

View Full Paper

Ask AI

Bookmark

Key result

Rosuvastatin added to standard heart failure therapy further prevented left ventricular dilatation, preserved cardiac function, and normalized inflammation in a rat model of HFpEF.

Why the study?

Does rosuvastatin added to standard heart failure therapy improve cardiac remodeling in a rat model of HFpEF?

Population

Two-month-old rats with hypertensive heart failure as a model of heart failure with preserved ejection…

Comparison

Rosuvastatin added to standard heart failure… vs Non-treated SHHF rats, SHHF rats treated with…

Design

Preclinical, randomly assigned

Follow-up

17 months

Authors

DGDulcenombre Gómez‐GarréPreventive Cardiology MGMa Luisa González‐RubioHospital Clínico San Carlos PMPaloma Muñoz‐PachecoHospital Clínico San Carlos

Discussion

Member takes

Implication

Should not change HFpEF practice; leaves open translation of rosuvastatin benefits from rat models to clinical trials.

Key Points

To evaluate whether adding rosuvastatin to standard heart failure therapy provides incremental improvements in cardiac structure and function in a rat model of hypertensive heart failure with preserved ejection fraction.
Two-month-old spontaneously hypertensive heart failure (SHHF) rats were randomly assigned to four groups: untreated controls, rosuvastatin alone, standard therapy (quinapril, torasemide, and carvedilol), or combination therapy.
Treatments were administered continuously for 17 months to evaluate long-term impacts on blood pressure, cardiac hypertrophy, left ventricular dilatation, fibrosis, and myocardial inflammation.
Standard anti-hypertensive therapy for 17 months significantly attenuated left ventricular chamber dilatation, cardiac hypertrophy, fibrosis, and inflammation compared with untreated rats.
Rosuvastatin alone prevented left ventricular dilatation and inflammation to a degree comparable to standard therapy, despite having no significant effect on blood pressure or cardiac hypertrophy.
Combining rosuvastatin with standard therapy provided superior protection by further preventing left ventricular dilatation, preserving cardiac function, and normalizing myocardial inflammation independently of blood pressure or plasma lipid changes.

Study Design

Type

RCT

Randomization

randomly assigned

Structured PICO

Does rosuvastatin added to standard heart failure therapy improve cardiac remodeling in a rat model of HFpEF?

Population

Two-month-old rats with hypertensive heart failure randomly assigned to four treatment groups and treated for 17 months.

Intervention

Rosuvastatin added to standard heart failure therapy (quinapril plus torasemide plus carvedilol) administered for 17 months

Comparator

Non-treated SHHF rats, SHHF rats treated with rosuvastatin alone, and SHHF rats treated with standard HF therapy alone

Outcome

Cardiac structure and function (including left ventricular chamber dilatation, cardiac hypertrophy, fibrosis, and inflammation)surrogate

In a rat model of HFpEF, adding rosuvastatin to standard heart failure therapy provided additional benefits in preventing left ventricular dilatation and reducing myocardial inflammation.

Cite This Study

Gómez‐Garré et al. (2010) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF). Rosuvastatin plus standard HF therapy (quinapril, torasemide, carvedilol) vs. Non-treated, rosuvastatin alone, or standard HF therapy alone was evaluated on Cardiac structure and function (LV chamber dilatation, cardiac hypertrophy, fibrosis, and inflammation). Rosuvastatin added to standard heart failure therapy further prevented left ventricular dilatation, preserved cardiac function, and normalized inflammation in a rat model of HFpEF.

synapsesocial.com/papers/6a79e4778d250a4360f3cb00 https://doi.org/10.1093/eurjhf/hfq101

Topics

HFrEF treatment Statin therapy Heart failure HFpEF management

View Full Paper

Ask AI

Bookmark

Rosuvastatin Added to Standard Heart Failure Therapy Improves Cardiac Remodelling in Heart Failure Rats with Preserved Ejection Fraction

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Topics

Rosuvastatin Added to Standard Heart Failure Therapy Improves Cardiac Remodelling in Heart Failure Rats with Preserved Ejection Fraction

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider